Stryker Co. (NYSE:SYK) Shares Sold by KCM Investment Advisors LLC

KCM Investment Advisors LLC lessened its stake in shares of Stryker Co. (NYSE:SYK) by 6.6% during the third quarter, Holdings Channel.com reports. The institutional investor owned 1,782 shares of the medical technology company’s stock after selling 125 shares during the period. KCM Investment Advisors LLC’s holdings in Stryker were worth $644,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of SYK. Centennial Bank AR boosted its holdings in shares of Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after purchasing an additional 48 shares during the last quarter. HBW Advisory Services LLC acquired a new stake in shares of Stryker during the third quarter worth $42,000. Hara Capital LLC acquired a new stake in shares of Stryker during the third quarter worth $42,000. Grove Bank & Trust boosted its holdings in shares of Stryker by 84.8% during the third quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock worth $44,000 after purchasing an additional 56 shares during the last quarter. Finally, DT Investment Partners LLC boosted its holdings in shares of Stryker by 114.3% during the third quarter. DT Investment Partners LLC now owns 135 shares of the medical technology company’s stock worth $49,000 after purchasing an additional 72 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of SYK stock opened at $390.08 on Friday. Stryker Co. has a 12-month low of $282.35 and a 12-month high of $392.70. The firm has a market capitalization of $148.71 billion, a price-to-earnings ratio of 41.81, a price-to-earnings-growth ratio of 2.89 and a beta of 0.91. The business has a 50 day simple moving average of $364.07 and a 200 day simple moving average of $347.33. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.77 by $0.10. The firm had revenue of $5.49 billion for the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. Stryker’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.46 earnings per share. On average, equities research analysts anticipate that Stryker Co. will post 12.06 EPS for the current year.

Insider Transactions at Stryker

In other Stryker news, VP M Kathryn Fink sold 2,121 shares of Stryker stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $370.00, for a total value of $784,770.00. Following the completion of the sale, the vice president now directly owns 10,042 shares in the company, valued at $3,715,540. The trade was a 17.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Viju Menon sold 600 shares of Stryker stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the sale, the insider now owns 9,069 shares of the company’s stock, valued at $3,219,495. This trade represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 67,381 shares of company stock valued at $24,825,275 over the last ninety days. Corporate insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Citigroup raised their price objective on Stryker from $406.00 to $411.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Needham & Company LLC lifted their price objective on Stryker from $393.00 to $409.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Evercore ISI increased their target price on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Truist Financial boosted their price objective on shares of Stryker from $370.00 to $380.00 and gave the stock a “hold” rating in a research note on Wednesday, October 30th. Finally, Wells Fargo & Company raised their target price on shares of Stryker from $381.00 to $405.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $393.65.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.